This bill requires the Government Accountability Office to study how prescription drug prices flow through the supply chain and create financial incentives for different companies involved in drug distribution. The study will examine compensation arrangements between pharmacy benefit managers, drug manufacturers, wholesalers, pharmacies, and other intermediaries, including whether fees based on drug prices might encourage companies to favor more expensive medications. The legislation is aimed at uncovering potential conflicts of interest where entities earning money based on a drug's price could have incentives to push higher-priced options. The Comptroller General must submit findings and recommendations to Congress within two years of the bill's enactment. This bill affects pharmaceutical companies, pharmacy benefit managers, health insurers, pharmacies, and ultimately patients who purchase prescription drugs, as it seeks to increase transparency about pricing dynamics in an industry facing ongoing scrutiny over drug costs.